You just read:

AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients

News provided by

Aridis Pharmaceuticals, Inc.

Dec 12, 2018, 07:30 ET